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ABSTRACT 
 
Human myxovirus resistance 2 (MX2/MXB) is an interferon-induced post-entry 
inhibitor of human immunodeficiency virus type-1 (HIV-1) infection. While the precise 30 
mechanism of viral inhibition remains unclear, MX2 is localized to the nuclear 
envelope, and blocks the nuclear import of viral cDNAs. The amino terminus of MX2 
(N-MX2) is essential for anti-viral function, and mutation of a triple arginine motif at 
residues 11 to 13 abrogates anti-HIV-1 activity. In this study, we sought to investigate 
the role of N-MX2 in anti-viral activity by identifying functionally relevant host-35 
encoded interaction partners through yeast-two-hybrid screening. Remarkably, five 
out of seven primary candidate interactors were nucleoporins or nucleoporin-like 
proteins, though none of these candidates were identified when screening with a 
mutant RRR11-13A N-MX2 fragment. Interactions were confirmed by co-
immunoprecipitation, and RNA silencing experiments in cell lines and primary CD4+ T 40 
cells demonstrated that multiple components of the nuclear pore complex and 
nuclear import machinery can impact MX2 anti-viral activity. In particular, the 
phenylalanine-glycine (FG) repeat containing cytoplasmic filament nucleoporin 
NUP214, and transport receptor transportin-1 (TNPO1) were consistently required for 
full MX2, and interferon-mediated, anti-viral function. Both proteins were shown to 45 
interact with the triple arginine motif, and confocal fluorescence microscopy revealed 
that their simultaneous depletion resulted in diminished MX2 accumulation at the 
nuclear envelope. We therefore propose a model whereby multiple components of 
the nuclear import machinery and nuclear pore complex help position MX2 at the 
nuclear envelope to promote MX2-mediated restriction of HIV-1.  50 
 3 
AUTHOR SUMMARY 
 
The movement of large molecules into the cell nucleus is regulated at specific sites 
within the nuclear envelope termed nuclear pores. To infect cells productively, human 
immunodeficiency virus type-1 (HIV-1) must traverse the nuclear envelope to enable 55 
integration of the viral DNA into the genomic DNA of host cells. We, and others, have 
previously identified a cell-encoded protein, human myxovirus resistance 2 (MX2), 
which is expressed upon initiation of an innate immune response and prevents 
accumulation of HIV-1 DNA within the nucleus, thus imposing a block to infection. 
Here, we reveal that components of the nuclear pore complex, and nuclear import 60 
machinery, are required for MX2-dependent inhibition of HIV-1 infection. We show 
that MX2, which is localized at the cytoplasmic face of the nuclear envelope, interacts 
with multiple protein components of the nuclear pore complex, as well as transport 
receptor transportin-1, via a functionally required triple arginine motif at its amino-
terminus. We speculate that these interactions facilitate MX2-mediated inhibition of 65 
HIV-1 nuclear import by situating the protein at the nuclear envelope. 
 
  
 4 
INTRODUCTION 
 70 
Human myxovirus resistance 2 (MX2/MXB) is an interferon-stimulated gene (ISG), and 
a key contributor to the type-1 interferon-induced post-entry inhibition of human 
immunodeficiency virus type-1 (HIV-1) infection (1-3).  The MX2-mediated block to 
HIV-1 infection occurs after reverse transcription, but prior to the nuclear import of 
pre-integration viral nucleoprotein replication complexes (1, 2). The precise 75 
mechanism of inhibition remains unclear, although the HIV-1 Capsid protein (CA) is 
believed to determine viral specificity since point mutations in CA can allow escape 
from MX2-mediated inhibition (1-4). Furthermore, MX2 has been shown to interact 
with synthetic Capsid-Nucleocapsid nanotubes in vitro. However, the relationship 
between CA binding and viral suppression is not straightforward, since mutations in 80 
CA that permit escape from viral inhibition do not prevent CANC nanotube 
interactions with MX2 (5-7).  
 
Human MX2 is a large dynamin-like GTPase, and is most closely related to 
human MX1/MXA. MX1 has long been established as a potent interferon-induced 85 
restriction factor for a range of DNA and RNA viruses including influenza A virus (IAV), 
though it does not inhibit retroviruses such as HIV-1 (8, 9). Indeed, despite sharing 
63% amino acid sequence identity and a similar structure and domain architecture (5), 
the viral specificities and mechanisms of action appear to differ considerably between 
MX1 and MX2. While GTPase activity is essential for the anti-viral function of MX1 90 
against IAV (10, 11), inactivating mutations in conserved residues within the GTPase-
domain of MX2 do not abrogate anti-viral activity against HIV-1 (1, 2). Both MX1 and 
 5 
MX2 can oligomerize, forming a variety of multimeric species from dimers and trimers 
to high-order oligomers (8, 12, 13), and recombinant MBP-tagged MX2 fusion proteins 
can form large helical assemblies in vitro (14). In a recent structure-function study by 95 
Gao et al, higher-order oligomerization of MX1 was found to be essential for anti-viral 
activity against IAV (15). However, while monomeric MX2 mutants are not anti-viral, 
higher-order oligomerization appears to be dispensable for MX2-mediated inhibition 
of HIV-1 (5, 13, 16).  
 100 
MX2 possesses an extended N-terminal domain that distinguishes it from MX1, 
and exists as two isoforms owing to the presence of an internal initiation methionine 
codon at position 26. However, only the longer 78 kDa isoform displays anti-HIV-1 
activity and is associated with the nuclear envelope (NE); the shorter 76 kDa isoform 
is cytoplasmic (as is human MX1), and is not anti-viral. Indeed we, and others, have 105 
previously shown that the N-terminal 91 amino acids of full-length MX2 are required 
for anti-viral activity (17, 18), and remarkably can confer anti-HIV-1 activity on 
heterologous scaffolds including MX1, the murine leukemia virus (MLV) restriction 
factor Fv1, and oligomerization-competent leucine-zippers (19). Previously, we 
identified a triple-arginine motif at positions 11 to 13 as essential for the anti-HIV-1 110 
activity of MX2 (19). Mutation of these three residues, either to alanine (RRR11-13A), 
or lysine (RRR11-13K), almost entirely abrogate anti-viral function, without observably 
disturbing NE localization (19). This motif has also been implicated in binding to HIV-1 
CA (20), though its precise role in virus suppression has remained unclear.  
 115 
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To address the role of the N-terminal domain in MX2 function, we therefore 
sought to identify biologically relevant host-encoded binding partners using yeast 
two-hybrid (Y-2-H) screening. Strikingly, most of the candidate interactors with the 
wild-type N-terminal sequence were nucleoporins (NUPs) or nucleoporin-like 
proteins. We then determined the functional importance of these interactions using 120 
a combination of biochemical, genetic and virological experiments: specifically, we 
confirmed these interactions through co-immunoprecipitation assays, and used RNA 
silencing-mediated depletion to demonstrate that multiple components of the nuclear 
pore complex (NPC) and the nuclear import machinery promote MX2-mediated 
inhibition of HIV-1 infection.  125 
 
 
RESULTS 
 
Multiple components of the nuclear pore complex interact with MX2 through its N-130 
terminal RRR11-13 motif. 
 
A yeast two-hybrid (Y-2-H) screen was performed to identify candidate interaction 
partners with the MX2 N-terminal domain (N-MX2). The N-terminal 91 amino acids of 
wild-type MX2, or mutant RRR11-13A MX2, were employed as bait fragments to 135 
screen against prey fragments from a human leukocyte cDNA library. Candidate 
interactors were assigned a Predicted Biological Score (PBS) (from A to F; A 
representing a very high confidence in the interaction, F representing experimentally 
proven artifacts as previously described (21)).  Candidate interactors with PBS scores 
 7 
of A, B or C with wild-type N-MX2 or mutant RRR11-13A N-MX2 are shown in Fig. 1A, 140 
with the complete lists of all identified genes displayed in S Table 1. For wild-type N-
MX2, five out of the seven candidate interactors are either FG-nucleoporins 
(nucleoporins containing phenylalanine-glycine repeat sequences; NUP358, NUP214 
and NUP98) or nucleoporin-like proteins containing FG-repeats (NUPL2/hCG1 and 
human Rev-interacting protein/hRIP). However, none of these proteins were 145 
recovered using the mutant RRR11-13A N-MX2 as bait. 
 
To validate these interactions, co-immunoprecipitation analyses were 
performed by co-expression of hemagglutinin (HA)-tagged wild-type MX2 or RRR11-
13 mutant MX2 and FLAG-tagged candidate interactors in 293T cells, HA-specific 150 
immunoprecipitation, and immunoblot detection of associated FLAG-tagged proteins 
(Fig. 1B). These data largely corroborated the interactions from the Y-2-H screen. 
NUP98, a 35 kDa C-terminal domain of NUP214 (the predicted site of interaction from 
the Y-2-H screen) and PNRC1 all exhibited a clear interaction with wild-type MX2, but 
almost no interaction with RRR-11-13A or the negative controls MX1 and green 155 
fluorescent protein (GFP) (S Table 2). hRIP exhibited a stronger interaction with MX2 
than RRR-11-13A (and virtually no interaction with the negative controls) while KLHL6 
and NUPL2 exhibited a comparable interaction with MX2 and RRR-11-13A. RUNX3, a 
predicted interactor of RRR-11-13A but not wild-type MX2, did indeed exhibit a 
stronger interaction with RRR-11-13A than wild-type MX2. Multiple experimentally 160 
varied co-immunoprecipitation studies with the regions of NUP358 predicted to 
interact with MX2 were unsuccessful.  
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Nuclear pore complex components and nuclear import factors are required for 165 
MX2-mediated inhibition of HIV-1. 
 
NUP358, NUP214, NUP98 and NUPL2 have been described as cytoplasmic filament 
nucleoporins (22) and have all been previously implicated in HIV-1 infection (23-29). 
These proteins are all components of the NPC and are localized, at least partially, at 170 
the cytoplasmic face of the NE. They all possess multiple FG-repeats, which have been 
proposed to act as sequential docking sites for nuclear transport receptors as they 
traverse the NPC (30), facilitating nuclear import/export of associated cargo (reviewed 
in (31)). MX2 imposes a barrier to HIV-1 infection that follows reverse transcription 
but precedes nuclear import of the viral cDNA (1). These nucleoporins and hRIP (which 175 
also resides on the NE cytoplasmic face) are, therefore, conceptually well placed to 
contribute to regulatory processes that influence HIV-1 nuclear import.  
 
We investigated whether these candidates, as well as selected other nuclear 
import factors and NPC components, are functionally linked with MX2 anti-viral 180 
activity. A focused siRNA “screen” incorporating other nucleoporins previously 
implicated in HIV-1 infectivity such as NUP153 (32, 33), NUP62 (34, 35) and transport 
receptor transportin-3 (TNPO3, also referred to as TRN-SR2) (36, 37), as well as the 
related transportin-1 (TNPO1, also called karyopherin-β2/KPNB2), was therefore 
performed. FLAG-tagged human MX2 and Photinus luciferase (negative control) 185 
constructs were overexpressed in U87-MG CD4+ CXCR4+ cells using the doxycycline-
inducible EasiLV lentiviral vector system (1). Prior to induction of expression, 
 9 
transduced cells were treated with experimental or control siRNAs. Following 
doxycycline treatment, cells were challenged with an HIV-1 based lentiviral vector 
(HIV-1/GFP) and transduction efficiency assessed after 48 h by flow cytometry (S Fig. 190 
1, Fig. 2A). Overexpression of human MX2 exhibited an ~18-fold inhibition of HIV-
1/GFP infection compared to the luciferase control after either treatment with a non-
targeting control siRNA pool or no siRNA treatment, consistent with previous 
observations (1, 13, 17, 19).  
 195 
Depletion of a number of nucleoporins (S Fig. 2) increased HIV-1 infection in 
MX2 expressing cells, indicating partial relief from MX2-mediated inhibition (we were 
unable to deplete NUPL2 using the siRNA pool tested). NUP214 depletion led to the 
most consistent and robust diminution in MX2-mediated inhibition, with 
simultaneous depletion of both NUP214 and TNPO1 exhibiting the most pronounced 200 
phenotype: ~6-fold inhibition of HIV-1 by MX2, corresponding to a ~3-fold reduction 
in MX2-mediated inhibition compared to the non-targeting siRNA control. This 
observation with NUP214/TNPO1 knock-down was then confirmed in a series of more 
targeted experiments, with the double depletion consistently reducing the MX2 anti-
viral effect by ~2 to 3-fold (Fig. 2B and 2C). Critically, MLV infection, which is not 205 
susceptible to MX2-mediated inhibition (1), was not affected by the depletion of 
NUP214/TNPO1 (Fig. 2D), and neither was the overall expression of MX2 (Fig. 2E). 
Interestingly, siRNA depletion of nucleoporins in general had a minimal general effect 
on HIV-1 infectivity in control (luciferase expressing) U87-MG cells, despite previous 
reports that several of the nucleoporins tested here are important for HIV-1 infection 210 
in other cell lines (24, 25, 27, 33) (S Fig. 1 and Fig. 2B). 
 10 
 
Due to the observed lack of impact of nucleoporin knockdown on infection of 
U87-MG cells, we asked whether functional redundancy between nucleoporin-
dependent HIV-1 nuclear import pathways in these cells may have occluded the 215 
detection of MX2-dependent infection phenotypes. We therefore investigated the 
nucleoporin requirements for MX2 inhibition in a second cell line, selecting HeLa cells 
since many previous studies relating to HIV-1 nuclear import have been conducted in 
this line. Human MX2 or CD8 (negative control) was overexpressed in HeLa cells using 
a puromycin selectable lentiviral vector system. Puromycin-selected transduced cells 220 
were treated with the same targeted siRNA pools used in the previous experiments 
prior to challenge with HIV-1/GFP, and monitoring of transduction efficiency was 
performed by flow cytometry (Fig. 3).  
 
In notable contrast to the observations in U87-MG cells (S Fig. 1 and Fig. 2), 225 
depletion of several nucleoporins reduced HIV-1 infectivity in control (CD8 expressing) 
cells (Fig. 3A). In agreement with previous observations in this cell line, depletion of 
NUP358 and NUP153 each reduced HIV-1 infectivity by ~5-fold, and depletion of 
TNPO3 reduced infectivity by ~8-fold, relative to treatment with a non-targeting 
siRNA). In cells treated with the non-targeting siRNA, MX2 exhibited an ~8-fold 230 
inhibition of HIV-1 infection (Fig. 3B). Specific siRNA depletion of many of the 
nucleoporins (confirmed by immunoblotting, S Fig. 3) significantly reduced the 
magnitude of MX2 inhibition (Fig. 3B); in particular, silencing of NUP214, NUP62, 
NUP153, NUP88, NUP358, NUP98 and transportins TNPO1 and TNPO3 each reduced 
the magnitude of MX2 inhibition of HIV-1 infection to below 3-fold. However, it is 235 
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important to recognize two caveats with this experiment: 1) the narrowing of the MX2 
inhibitory phenotype in HeLa cells silenced for NUP358, NUP153 or TNPO3 is largely 
driven by reduced infection of control cells rather than the restoration of infection in 
cells harboring MX2 (i.e., in contrast to what we describe in U87-MG cells, S Fig. 1 and 
Fig. 2), and 2) the silencing of certain nucleoporins can result in the reduced expression 240 
of nucleoporins additional to the intended target (S Fig. 3), thus making it impractical 
to ascribe activity to single proteins in some cases. Notably, knock-down of NUP214, 
NUP62 or NUP98 had minimal effects (<2-fold) on HIV-1 infection in control cells, 
indicating that each of these nucleoporins promote MX2 anti-viral function. Depletion 
of some of the other candidates from the Y-2-H screen such as hRIP, had no effect on 245 
MX2-mediated inhibition (Fig. 3). 
 
 
MX2 interacts with TNPO1, in part via the N-terminal RRR11-13 motif 
 250 
We next wished to confirm whether endogenous FG-nucleoporins interact with IFN-
induced endogenous MX2. U87-MG cells were first treated with either a non-targeting 
control siRNA, or anti-NUP214 siRNA followed by the addition of IFN for 24 h to 
induce MX2 expression. Immunoprecipitation with mab414, a mouse monoclonal 
antibody which recognizes FG-repeat regions within multiple nucleoporins including 255 
NUP358, NUP214, NUP153 and NUP62 (38), was then performed using cell lysates, 
and associated MX2 was detected by immunoblotting using an MX2-specific antibody 
(Fig. 4A). Immunoblots of the cell lysate (INPUT) material show efficient IFN-mediated 
induction of MX2, and specific depletion of NUP214 following siRNA treatment. MX2 
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was detected in IFN-induced samples immunoprecipitated with mab414, but not with 260 
the negative control GFP-specific antibody (Fig. 4A), demonstrating an interaction with 
endogenous FG-nucleoporins. Depletion of NUP214 visibly reduced but did not ablate 
this interaction (although MX2 levels were noticeably higher in NUP214 siRNA treated 
samples) implying that at least one other nucleoporin recognized by mab414 can also 
interact with MX2.  265 
 
Since NUP214 and TNPO1 were required for full MX2-mediated HIV-1 
inhibition in both U87-MG cells and HeLa cells, potential interactions between these 
proteins and MX2 were explored further. A series of co-immunoprecipitation 
experiments were performed using 293T cells transfected with HA- and FLAG-tagged 270 
constructs, HA-specific immunoprecipitation, and immunoblot detection of 
associated FLAG-tagged proteins (Fig. 4B and 4C). TNPO1 interacts with wild-type 
MX2, but not GFP or MX1 (Fig. 4B), whereas the interaction between TNPO1 and the 
RRR11-13A mutant is diminished, despite a higher level of RRR11-13A present in the 
immunoprecipitated material, suggesting that arginine residues 11-13 are important 275 
for the interaction (Fig. 4B, S Table 2). TNPO1 does not interact with the C-terminal 
domain of NUP214, though the interaction between NUP214 and MX2 is again 
demonstrated (Fig. 4C). Observed interactions between MX2 and both NUP214 and 
TNPO1 were also demonstrated by similar experiments performed with FLAG-specific 
immunoprecipitation instead of HA-specific immunoprecipitation (Fig. 4D). Additional 280 
attempts to explore the possible formation of a ternary NUP214-MX2-TNPO1 complex 
were unsuccessful, but perhaps this is to be expected since both interactions depend 
 13 
upon the integrity of the triple-arginine motif at positions 11 to 13 and may therefore 
be mutually exclusive. 
 285 
 
Assessment of endogenous MX2, NUP214 and TNPO1 function during IFN-mediated 
inhibition of HIV-1 
 
Since endogenous, IFN-induced, MX2 is able to interact with NPC proteins, we next 290 
investigated the role played by NUP214 and TNPO1 in endogenous MX2 function 
during the inhibition of HIV-1 by IFN. An U87-MG CD4+ CXCR4+ derived cell line was 
engineered where the MX2 alleles were inactivated using CRISPR-Cas9 genome 
editing, and the effect of NUP214 and/or TNPO1 depletion by siRNA treatment was 
analyzed. As a control, we used siRNAs targeting MX2, as well as a CRISPR-Cas9 control 295 
cell line (CTRL CRISPR). As expected, IFN treatment of CTRL CRISPR cells resulted in a 
severe reduction in the percentage of infected cells (Fig. 5A). SiRNA-mediated 
silencing of MX2 reduced the suppression of virus infection caused by IFN by ~50% 
when compared with the CTRL siRNA. Importantly, knock-down of NUP214, TNPO1 or 
both proteins together significantly reduced the effect of IFN on viral infectivity to 300 
levels similar to that seen in cells depleted of MX2 alone. 
 
In the MX2 CRISPR cell line, the reduction of viral infection observed after IFN 
treatment (and transfection with CTRL siRNA) was substantially reduced when 
compared to the CTRL CRISPR cells (4.3- versus 12.4-fold reduction, Fig. 5A-B; note the 305 
absence of MX2 in the IFN-treated cells in Fig. 5B according to immunoblot analysis). 
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Critically, no further reduction of infectivity was observed in the MX2 CRISPR cells 
when MX2, NUP214, TNPO1 or NUP214/TNPO1 together were depleted by siRNA 
treatment. The only noticeable difference observed in these cells was a modest 
increase in infectivity in cells depleted of NUP214 and not treated with IFN, which 310 
consequently registered as a slightly greater IFN effect upon NUP214 depletion. 
Taken together, these results reconfirm that endogenous MX2 contributes to the 
inhibition of HIV-1 by IFN, and demonstrate that the contributions of NUP214 and 
TNPO1 to the anti-viral effect of IFN are dependent on MX2. 
 315 
In an attempt to provide additional evidence for the role(s) of NUP214 and 
TNPO1 in MX2 in anti-viral activity using a more physiologically relevant model, we 
tested the effect of depleting these two proteins, as well as MX2, in primary CD4+ T 
cells from 4 donors by shRNA-mediated silencing. Using NL4.3/Nef-IRES-Renilla as the 
challenge virus, depletion of MX2 yielded clear relief from the effect of IFN in 3 of 4 320 
donors (Fig. 5C). Upon targeting of TNPO1, all donors displayed a diminution in the 
effects of IFN, whereas only 2 donors showed an effect following NUP214 knock-
down. However, analysis of cellular mRNA levels revealed that the shRNA-mediated 
suppression of NUP214 transcripts was relatively inefficient, likely explaining its 
evidently weaker phenotypic effect in these primary cell cultures (Fig. 5D). These data 325 
are in concordance with the data obtained in cell lines, and confirm the contributions 
of MX2, NUP214 and TNPO1 to the IFN response against HIV-1 infection. 
 
 
Nuclear envelope targeting of MX2 requires both NUP214 and TNPO1 330 
 15 
 
Human MX2 localizes at the NE (17, 39); we therefore hypothesized that the molecular 
interactions described herein may facilitate tethering of MX2 to the cytoplasmic face 
of NPCs. Confocal microscopy was performed on HeLa cells stably expressing C-
terminally FLAG-tagged MX2 and treated with control non-targeting siRNA or siRNAs 335 
specific for NUP214 and/or TNPO1 (Fig. 6; panel B depicts visual scoring of MX2 
localization for ~100 cells per sample).  In cells treated with control siRNA, MX2 
exhibited staining at the NE as well as diffuse staining throughout the cytoplasm (2, 
17, 19). NUP214 was also localized to the NE as in previous reports (26), and TNPO1 
exhibited both nuclear and cytoplasmic staining as has also been described (40). 340 
Treatment of cells with siRNA targeting either NUP214 or TNPO1 led to their 
respective depletion, but with no apparent effect on MX2 localization. However, in 
cultures doubly depleted for NUP214 and TNPO1, MX2 was significantly re-distributed 
to the cytoplasm with less pronounced NE accumulation. These findings infer that 
NUP214 and TNPO1 function in the NE targeting and localization of MX2; nevertheless, 345 
given that the single gene knock-downs yielded no significant alterations in MX2 
localization, we speculate that the roles of each protein in NE targeting can be 
provided by redundantly acting host proteins.  
 
 350 
DISCUSSION 
 
In seeking to define host co-factors required for MX2 inhibition of HIV-1, we started 
by performing an unbiased Y-2-H screen using the functionally essential N-terminal 
 16 
domain as bait. Remarkably, most of the candidate interactors with wild-type N-MX2 355 
were members of a specific subfamily of nucleoporins, the cytoplasmic filament FG-
nucleoporins (NUP358, NUP214, NUP98) or FG-repeat containing nucleoporin-like 
proteins also associated with the cytoplasmic face of the NE (NUPL2, hRIP) (Fig. 1A; 
Fig. 7). None of these candidates scored as interacting with the inactive mutant R11-
13A thereby attesting to their likely biological relevance, and all interactions with wild-360 
type MX2, with the exception of that with NUP358, were validated by co-
immunoprecipitation (Fig. 1B). Though we could not confirm the MX2—NUP358 
interaction, data obtained through immunoprecipitation of endogenous nucleoporins 
with IFN-induced MX2 suggested that at least one other nucleoporin in addition to 
NUP214 on the cytoplasmic face of the NPC (which includes NUP358) may interact 365 
with MX2 (Fig. 4A).  
 
MX2 has previously been proposed to suppress HIV-1 infection by inhibiting 
the nuclear import of viral replication complexes, a view supported by the NE 
localization of the active 78 kDa isoform of MX2 (1, 2, 41). Here, we have used RNA 370 
silencing to demonstrate that certain members of the family of cytoplasmic filament 
FG-nucleoporins are required for full-anti-viral activity of MX2 (Fig. 2, Fig. 3), including 
some that we have shown to interact with the MX2 N-terminal domain. In U87-MG 
cells, significant functional redundancy appeared to exist, although depletion of 
certain nucleoporins, particularly NUP214, as well as the transport receptor TNPO1, 375 
elicited a significant reduction in the potency of MX2-mediated inhibition (S Fig. 1, Fig. 
2). Importantly, we further confirmed that NUP214 and TNPO1 are key determinants 
of the HIV-1 inhibitory function of endogenous MX2 during the IFN response: 
 17 
depletion of NUP214 and/or TNPO1 significantly curtailed the anti-viral effect of IFN, 
but only in cells expressing MX2 (Fig. 5A-B). In addition, we also used RNA silencing to 380 
show, for the first time, that MX2 contributes to IFN-mediated suppression of HIV-1 
in primary CD4+ T cells (Fig. 5C). Consistent with our findings in cell line systems, 
silencing of TNPO1 or NUP214 (albeit to a lesser extent, and possibly due to less 
efficient silencing) also attenuated the effects of IFN.  
 385 
A considerable body of prior evidence has shown that HIV-1 requires the 
presence of specific nucleoporins to facilitate trafficking of viral replication complexes 
through the NPC (in studies where MX2 was not present)  (24, 25, 42). However, our 
experiments in U87-MG cells indicated that there is no specific requirement for 
particular nucleoporins for HIV-1 infection, implying effective functional redundancy 390 
between multiple nuclear import factors/pathways in MX2’s absence.  In contrast, 
HIV-1 infection in HeLa cells exhibited a marked requirement for specific nucleoporins, 
particularly NUP358 and NUP153 and the transport receptor TNPO3, in agreement 
with previous observations (Fig. 3) (24, 25, 42). Perhaps mirroring such selectivity, a 
stronger dependence on certain nucleoporins and transport receptors for MX2-395 
mediated inhibition was also observed in HeLa cells, with depletion of NUP214, 
NUP88, NUP358, NUP153 or TNPO3 eliciting ~4-fold reductions in MX2-mediated 
inhibition, and depletion of TNPO1, NUP62 and NUP98 eliciting ~3-fold reductions in 
MX2’s effect (Fig. 3). However, the inherent dependence of HIV-1 infection upon 
NUP358, NUP153 and TNPO3 in HeLa cells confounds this analysis since their 400 
depletion results in less efficient infection regardless of MX2 expression. Taken 
together, observations in these cell lines suggest that multiple nucleoporins can 
 18 
contribute to MX2-mediated inhibition of HIV-1, but that significant functional 
redundancy exists and the requirements for specific nucleoporins vary between cell 
lines. Nevertheless, NUP214 and TNPO1 were consistently important for full MX2 anti-405 
HIV-1 function, even in CD4+ T cells, and their depletion did not significantly impair 
infection in the absence of MX2: we therefore conclude that these proteins are 
particularly influential in promoting the anti-viral activity of MX2.  
 
The pathway(s) through which nuclear import of HIV-1 proceeds remains 410 
unclear, as do the molecular details of inhibition by MX2. There is evidence to suggest 
that HIV-1 CA is a key specificity determinant in both processes (43). Certain 
engineered mutations in CA permit escape from MX2-mediated restriction, including 
at positions P90 and G89 (the cyclophilin A (CYPA) binding loop), N74 and N57 (the 
CPSF6 binding site), and T210, N57 and G208 (1, 2, 18), However, current in vitro 415 
evidence indicates that such mutant CA proteins retain the ability to interact with MX2 
(5, 7). CypA is required for MX2 inhibition in some cell lines (3) but not others, 
including CD4+ MT4 cells where CA mutant viruses that have lost the ability to interact 
with CYPA remain MX2 resistant (18). Many of the same CA mutations that enable 
escape from MX2 have also been shown to influence HIV-1’s requirement for certain 420 
nucleoporins and transport factors during nuclear import. For instance, NUP358 can 
interact with CA directly through its cyclophilin domain, and mutations in CA at 
positions P90 and G89 reduce the dependence on both NUP358 and NUP153 for 
nuclear import in HeLa cells (24, 33). The dependence of nuclear import on TNPO3 
also appears to map to CA (44), with mutations at positions N74 and N57 within the 425 
CPSF6 binding site promoting use of a TNPO3 independent pathway (24). However, 
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the mechanism(s) through which these preferences exert their effects remains 
obscure. 
 
Thus far, NUP214 has been primarily studied in the context of CRM-1 430 
dependent nuclear export (26, 45), including that of HIV-1 viral RNAs (28). However, 
NUP214 is required for docking of adenovirus (Ad) particles at the NPC and 
subsequent disassembly and nuclear import of the viral DNA (46). Furthermore, 
through interaction assays with purified NEs from rat liver nuclei, and crosslinking 
studies with recombinant protein, the Ad2 capsid was shown to interact with the FG-435 
repeat containing C-terminal domain of NUP214 (46) (also a site of MX2 interaction, 
Fig. 1B). TNPO1 is a member of the karyopherin-β family, and while few previous 
studies have addressed its function in the HIV-1 life cycle, its role in nuclear 
translocation is believed to be restricted to import (reviewed in (47)). Many cargoes 
imported by TNPO1 possess a proline-tyrosine nuclear localization signal (PY-NLS) 440 
motif, a weak consensus sequence generally located within a basic and structurally 
disordered domain (48), with reported cargoes including CPSF6 and HIV-1 Rev (47). 
Though the N-terminal domain of MX2 contains part of the consensus motif (R/H/X-
X2-5-PY), no clear role for it in HIV-1 suppression is suggested since the inactive RRR11-
13 mutant is still capable of binding to TNPO1 (albeit at reduced levels, Fig. 4B, S Table 445 
2), and mutation of residues within the consensus region do not interfere with anti-
HIV-1 activity (19). TNPO1, like other members of the karyopherin-β family, interacts 
with FG-repeat regions of nucleoporins, facilitating recruitment of these transport 
receptors and their associated cargoes to the NPC (47). Earlier biochemical studies 
have also shown that recombinant TNPO1 can interact with NUP358, NUP214, 450 
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NUP153, NUP98, and NUP62 from Xenopus egg extracts (49), but our studies failed to 
detect an interaction between TNPO1 and the C-terminal region of human NUP214 
(consistent with a previous study (45)), despite the fact that the majority of NUP214’s 
FG-repeats are present within this region of the protein (Fig. 4).  
 455 
 Taken together, this work invokes a model where NUP214 and TNPO1 are each 
important for the anti-viral activity of MX2, but that their contributions are both 
subject to degrees of cell type variation and redundancy, particularly in the case of 
NUP214 where additional FG-nucleoporins may serve similar role(s) in some cell types. 
Nevertheless, in light of their known functions and sites of localization (Fig. 7), we 460 
propose a model in which interaction with TNPO1 helps recruit MX2 to the NPC, where 
MX2 can subsequently accumulate through interactions with NUP214 and other 
nucleoporins. The notion of redundant functionality among FG-nucleoporins for MX2 
binding and localization is reminiscent of nucleoporin interactions with nuclear 
transport receptors (31, 50), and is illustrated by our Y-2-H and co-465 
immunoprecipitation data (Fig. 1), the sustained NE accumulation of the RRR11-13A 
mutant (19), as well as by the incomplete inhibition of MX2 function following efficient 
RNA silencing interventions (Fig. 2, Fig. 3).  
 
 Once localized at the NPC, MX2 is presumably then positioned to inhibit the 470 
nuclear import of HIV-1 nucleoprotein replication complexes (1, 2). Current data 
suggest that the N-terminal domain of MX2 is again pivotal for activity, most likely via 
interactions with the viral CA protein (5, 17, 18, 20), thus adding a further interacting 
partner to the list of MX2 ligands. That said, it should also be acknowledged that a 
 21 
significant proportion of MX2 is cytosolic rather than NE localized (Fig. 6) (17), and that 475 
interactions with viral replication complexes could initiate away from the NPC. One 
set of critical questions that is raised is: what are the specific roles(s) of the 
interactions between MX2, nucleoporins and CA, and how do they relate to one 
another in the context of viral inhibition? While nucleoporin binding to CA is thought 
to be important for HIV-1 translocation through the NPC, as well as ordered capsid 480 
disassembly (uncoating), MX2 interferes with these processes. Though this could be 
accomplished by MX2 competitively impeding CA-nucleoporin interactions, we favour 
the idea that MX2 inhibits HIV-1 infection through a specific process that targets viral 
replication complexes, a view that is supported by the noted ability of CA mutants to 
evade MX2. Another related question is: how does the N-terminal domain of MX2 485 
accommodate a series of potentially sequential and competing interactions? A 
possible contributing solution is provided by MX2 oligomerization (5, 13), which may 
afford an MX2 oligomer the capacity to contact simultaneously different ligands, for 
instance, allowing CA binding while retaining NPC tethering. In sum, there is much to 
be resolved concerning the nature, orchestration and spatiotemporal ordering of the 490 
key molecular interactions and mechanistic processes that underpin MX2-mediated 
viral restriction at the NE.  
 
Note added during revision 
During the review of this work, Kane et al., reported the use of RNA silencing to show 495 
that several nucleoporins impact HIV-1 infection as well as MX2 anti-viral function 
(51). Our results are in good general agreement with their findings that depletion of 
NUP214 or TNPO1 impair MX2 anti-viral function in HeLa cells, and also with the 
 22 
apparently variable nucleoporin requirements for HIV-1 infection and MX2 activity 
among different cell lines.  500 
 
 
MATERIALS AND METHODS 
 
Cell culture and plasmid constructs 505 
 
Human 293T cells, HeLa cells and parental U87-MG cells were obtained from the 
American Tissue Culture Collection (ATCC). The generation of the U87-MG CD4+ 
CXCR4+ cell line has been described (1). All cell lines were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with fetal bovine serum (10%), L-510 
glutamine and penicillin-streptomycin. Human primary CD4+ T cells were 
obtained through the Infectious Diseases BioBank at King’s College London (ethics 
reference MM2-220518) and were isolated from peripheral blood mononuclear 
cells (PBMCs) of anonymous healthy volunteer donors with written consent under 
overall permission from the Southampton and South West Hampshire Research 515 
Ethics Committee (B) (approval REC09/H0504/39+5). CD4+ T cells were purified 
by density gradient centrifugation using LymphoPrep (Axis-Shield) and isolated 
by negative selection using the CD4+ T Cell Isolation Kit (Miltenyl Biotec) following 
manufacturer’s instructions. Activation of the cells was achieved using Dynabeads 
Human T-Activator CD3/CD28 (ThermoFisher) and 50 U/ml recombinant IL-2 520 
(rIL-2) (Roche) for 48 h in medium consisting of RPMI 1640-GlutaMAX containing 
10% heat-inactivated autologous serum, 100 U/ml penicillin and 100 U/ml 
streptomycin. After activation, cells were maintained in medium containing 30 
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U/ml of rIL-2. IFN-2b (Merck, Sharpe & Dohme Corp.) was added to cultures for 
24 h prior to infection, as indicated.  525 
 
Construction of pCAGGS based expression constructs encoding FLAG- or HA-
tagged GFP, MX1 or MX2 has been described previously (13, 17). pCAGGS R11-13A 
MX2-HA was generated by replacing the cDNA encoding the first 25 amino acids 
from MX2-HA with the mutated version from R11-13 MX2-FLAG (described 530 
previously(19)) using NotI and EcoRI. To generate FLAG-NUP214 CTD (~40 kDa 
C-terminal fragment), the cDNA encoding the C-terminal amino acids (positions 
1681-2080) of NUP214 (IMAGE clone BC105998) were PCR amplified with an N-
terminal FLAG tag and cloned into pCAGGs. pCAGGs FLAG-KLHL6, PNRC1-FLAG, 
FLAG-NUPL2 and RUNX3-FLAG were generated by PCR amplification of full-535 
length cDNAs from IMAGE clones BC032348, BC018112, BC107583, and 
BC013362 respectively. pCAGGs FLAG-TNPO1 and HA-TNPO1 were generated 
from PCR amplification of the full-length cDNA from IMAGE clone BC040340. 
FLAG-NUP98 and T7-hRIP were gifts from Drs Maria Teresa Catanese and Chad 
Swanson, respectively. EasiLV based lentiviral expression vectors 540 
(pRRL.sin.cPPT.(7TetOCMV/CDS.IRES.rtTA3-2A-E2-Crimson)antisense.WPRE) 
encoding MX2-FLAG or Photinus pyralis luciferase-FLAG; lentiviral vectors 
conferring puromycin selection (LV-puromycinR) (pRRL.sin.cPPT.CMV/CDS-
IRES-puromycinR.WPRE) constitutively expressing CD8-FLAG or MX2-FLAG; and 
the NL4-3/nef-IRES-Renilla reporter virus (which expresses Renilla luciferase 545 
from an internal ribosome entry site, IRES) have been described (1, 13).  
 
Yeast two-hybrid screen 
 24 
 
A yeast two-hybrid screen to probe for interaction partners with the N-terminal 550 
domain of MX2 was performed by Hybrigenics Services (ULTImate Y2HTM, 
www.hybrigenics-services.com). Amino acids 1 to 91 of human MX2 (N-MX2) 
were used as bait to screen against a human leukocyte cDNA library. Predicted 
interactions with native N-MX2 were compared to those identified using mutant 
RRR11-13A N-MX2 as a bait domain. Interactions were awarded a Predicted 555 
Biological Score (PBS) to assess the reliability of each interaction, primarily based 
on the number of independent prey fragments identified for each interaction 
compared to the probability of random selection (21). For interactions awarded 
‘A’ there is ‘very high confidence’ in the interaction, for those awarded ‘C’ there is 
‘good’ confidence in the interaction, and those awarded F have been 560 
experimentally demonstrated to be technical artifacts. 
 
Co-immunoprecipitation 
 
For co-immunoprecipitation of ectopically expressed affinity-tagged proteins, 565 
293T cells were seeded in 6-well plates and co-transfected with pCAGGs based 
plasmids encoding triple-HA tagged and FLAG- or T7-tagged constructs using 
polyethylenimine. After ~30 h, cells were lysed in either hypotonic lysis buffer (10 
mM Tris-HCl pH 8.0, 10 mM KCl, 1 × protease inhibitor cocktail (Roche)) by 
Dounce homogenization in experiments with PNRC1, KLHL6 and hRIP; or isotonic 570 
lysis buffer (1 × phosphate buffered saline, 0.5% Triton-X100, 1 × protease 
inhibitor cocktail) and lysed by sonication (20 s) for all other experiments. Lysates 
were cleared by centrifugation at 1,500 × g for 10 min, and for hypotonic lysates, 
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KCl and Triton X-100 were added at final concentrations of 100 mM and 0.3%, 
respectively. A sample from each whole cell lysate was saved in order to confirm 575 
protein expression levels. HA-tagged proteins were immunoprecipitated using 
anti-HA magnetic beads (Pierce) for 2 h at 4°C, or FLAG-tagged proteins were 
immunoprecipitated with anti-FLAG (M2) magnetic beads (Sigma) under the 
same conditions. Beads were washed a further 4 times in wash buffer for 
hypotonic lysates (10 mM Tris-HCl pH 8.0, 200 mM KCl, 0.3% Triton X-100) or 580 
isotonic lysis buffer for isotonic lysates before the addition of sample buffer (200 
mM Tris-HCl pH 6.8, 5.2% SDS, 20% glycerol, 0.1% bromophenol blue, 5% β-
mercaptoethanol). HA-, FLAG- and T7 tagged proteins were resolved on 10% 
acrylamide gels by SDS-PAGE and detected by immunoblotting using HRP-
conjugated anti-HA (rat monoclonal 3F10, Sigma), anti-FLAG (mouse monoclonal 585 
M2, Sigma), or anti-T7 antibody (mouse monoclonal, Sigma). Images were 
visualized by chemiluminescence (ECL western blotting substrate, Pierce) on a LI-
COR Odyssey Fc imaging system (LI-COR) and band intensities of input and 
precipitated proteins were quantified using ImageJ software. 
 590 
For co-immunoprecipitation of endogenous FG-nucleoporins and IFN-induced 
MX2, U87-MG CD4+ CXCR4+ cells were transfected twice, 24 h apart, with siRNAs 
targeting NUP214 (Dharmacon siGENOME smartpool) or a non-targeting control 
siRNA (Dharmacon). After 72 h, cells were treated with IFN (500 U/ml) for 24 h 
to induce MX2 expression, prior to harvesting. Cells without IFN were included as 595 
a negative control for MX2 induction. Harvested cells were lysed in isotonic lysis 
buffer, sonicated, and the lysate cleared as described previously. FG-nucleoporins 
were immunoprecipitated with mouse monoclonal antibody mab414(38) 
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conjugated to protein G magnetic beads (Invitrogen) for 2 h at 4oC. An anti-GFP 
mouse monoclonal antibody (Roche) was used as a negative control. Beads were 600 
washed with isotonic lysis buffer, before addition of sample buffer. 
Immunoprecipitated endogenous FG-nucleoporins NUP358, NUP214, NUP153 
and NUP62 were detected by immunoblotting with mab414 after SDS-PAGE on 
6% acrylamide gels, and MX2 was detected by immunoblotting with anti-MX2 goat 
polyclonal antibody (N17, Santa Cruz Biotechnology). Bound primary antibodies 605 
were detected with HRP-conjugated anti-mouse or anti-goat immunoglobulin 
secondary antibodies and visualized by chemiluminescence. 
 
HIV-1 vector infectivity assays 
 610 
For experiments in U87-MG CD4+CXCR4+ cells, ectopic expression of MX2 was 
achieved by transduction of cells with doxycycline-inducible EasiLV lentiviral 
vectors encoding FLAG-tagged human MX2 (or a FLAG-tagged luciferase control 
construct) for 6 h. After a rest period of 48 h, transduced cells were transfected 
twice, 24 h apart, with a panel of siRNAs (all human siGENOME smartpools, 615 
Dharmacon) at 20 nM concentration using Lipofectamine RNAiMAX reagent 
(Invitrogen). After 16 h, transgene expression was induced by the addition of 0.5 
μg/ml doxycycline for 72 h, prior to viral challenge. EasiLV transduction efficiency 
was typically above 90% and was assessed by measuring the percentage of cells 
expressing E2-crimson (co-expressed via an IRES) by flow cytometry (FACSCanto 620 
II; BD Biosciences). To assess HIV-1 infectivity, cells were challenged with HIV-
1/GFP, a vesicular stomatitis virus G protein (VSV G)-pseudotyped 8.91 HIV-1 Gag-
Pol based cytomegalovirus (CMV) immediate early-enhanced green fluorescent 
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protein lentiviral vector as described previously (13). Productive infection was 
enumerated by flow cytometry as the percentage of E2-crimson-positive cells 625 
expressing GFP at 48 h post infection. Preparation of EasiLV particles and 
challenge HIV-1/GFP vector stocks has been described (1, 17). In experiments 
measuring the effect of MX2, NUP214 and/or TNPO1 depletion by siRNA during 
an IFN response, CTRL CRISPR or MX2 CRISPR U87-MG cells were doubly 
transfected 24 h apart with 10 nM siRNA in 24-well plates. 8 h later, cells were 630 
split into two populations and seeded in 96 well plates. One population was 
treated with IFN while the other one was left untreated. 24 h later cells were 
challenged with HIV-1/GFP as described.  
 
For experiments in HeLa cells, constitutive overexpression of MX2 was achieved 635 
by transduction of cells with lentiviral vector LV-PuromycinR expressing FLAG-
tagged human MX2 (or a FLAG-tagged CD8 control construct) (1). After 72 h, 
transduced cells were selected with 1 μg/ml puromycin for a further 72 h (100% 
cell mortality for non-transduced cells). Selected cells were treated twice with 
siRNA, and challenged with HIV-1/GFP, as described previously. In both cell lines, 640 
efficiency of siRNA-mediated silencing prior to challenge was assessed by 
immunoblotting. Cell pellets were lysed in sample buffer, resolved by SDS-PAGE, 
and detected using the following primary antibodies: mab414 (FG-nucleoporins 
NUP358, NUP214, NUP153, NUP62), anti-NUP98 (rat monoclonal 2H10, Abcam), 
anti-hRIP (goat polyclonal, Santa Cruz Biotechnology), anti-KLHL6 (rabbit 645 
monoclonal, Abcam), anti-TNPO1 (mouse monoclonal D45, Abcam), anti-α-
tubulin (mouse monoclonal, Sigma), and anti-Hsp90 (rabbit; Santa Cruz 
Biotechnology), anti-Nup188 (rabbit polyclonal, Abcam), anti-TNPO3 (mouse 
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monoclonal, Abcam), anti-Nup88 (rabbit polyclonal, Abcam), anti-hRIP (rabbit 
polyclonal, Abcam) or anti-PNRC1 (rabbit polyclonal, antibodies-online.com). 650 
Bound primary antibodies were detected with HRP-conjugated anti-mouse, anti-
rat, anti-rabbit or anti-goat immunoglobulin secondary antibodies and visualized 
by chemiluminescence 
 
CRISPR-Cas9 genome editing of U87-MG cells 655 
 
U87-MG cells were transduced with VSV-G-pseudotyped HIV-1 lentiviral vector 
(LV) bearing plentiCRISPRv2. Specific guide RNAs targeting MX2 or RFP (as the 
control) were cloned into BsmBI-linearized lentiviral vector pLentiCRISPRv2 
using the oligonucleotides (forward/reverse) caccgAATTGACTTCTCCTCCGGTA / 660 
aaacTACCGGAGGAGAAGTCAATTc for MX2 and caccgCTCAGTTCCAGTACGGCTCCA 
/ aaacTGGAGCCGTACTGGAACTGAGc for RFP. Transduced cells were selected with 
1 µg/ml puromycin. Single-cell clones were obtained by limiting dilution and 
grown in a 96-well plate in the absence of puromycin and MX2 depletion was 
validated by immunoblotting.  665 
 
shRNA-mediated gene silencing 
 
Modified versions of the HIV-1 based lentiviral vector pHRSIREN-S-SBP-∆LNGFR-
W (52) where the selectable marker for antibody-free magnetic cell sorting (SBP-670 
∆LNGFR) was replaced by GFP (CTRL and TNPO1) or E2-crimson (MX2 and 
NUP214) for cytometric analysis of transduction were used for gene silencing in 
primary CD4+ T cells. The shRNA targeting sequences for MX2, NUP214 and 
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TNPO1 were AAGATGTTCTTTCTAATTG, GGTGAGAATCTTTGACTCC and 
GCAAAGATGTACTCGTAAG, respectively. Lentiviral vectors were obtained by 675 
cotransfection of 293T cells with VSV-G, p8.91 and the modified pHSIREN-S vector 
at a ratio of 0.5:1:1.5, respectively. Supernatants containing lentiviral particles 
were concentrated by ultracentrifugation and human primary CD4+ T cells were 
transduced by spin-infection at 2000 x g for 2 h at room temperature. 48 h after 
transduction, 2.5 x 104 cells/well were seeded in a 96 well plate and treated or not 680 
with IFN. 24 h later, cells were challenged with 30 ng p24Gag of NL4.3/Nef-IRES-
Renilla at 2000 x g for 2 h at room temperature. After 48 h, infection was assessed 
by measuring Renilla luciferase activity on a luminometer.  
 
Fluorescence microscopy 685 
 
Hela cells stably expressing MX2 bearing a C-terminal FLAG-tag were obtained by 
transduction with LV-PuromycinR (1) encoding MX2-FLAG and selection with 1 
µg/ml puromycin for 72 h. Stable cells were then transfected twice, 24 h apart, 
with 20 nM siRNA in 24-well plates as described above. Transfected cells were 690 
seeded onto coverslips at ~50,000 cells per well in 12-well plates; 24 h later, cells 
were washed with 1x phosphate buffer saline and fixed in 4% paraformaldehyde 
(EM Sciences) for 15 min, permeabilized with 0.2% Triton X-100 for 15 min, and 
blocked/quenched in buffer NGB (50 mM NH4Cl, 2% goat serum, 2% bovine serum 
albumin) for 1 h. MX2-FLAG was detected using a mouse anti-FLAG monoclonal 695 
M2 (Sigma) and secondary donkey anti-mouse antibody conjugated to Alexa 594 
(Invitrogen). Endogenous NUP214 was detected using rabbit anti-NUP214 
polyclonal antibody (Abcam ab70497) and secondary donkey anti-rabbit 
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antibody conjugated to Alexa 488 (Invitrogen). Endogenous TNPO1 was detected 
using rat anti-TNPO1 monoclonal L5G3 (antibodies-online.com) and secondary 700 
goat anti-rat antibody conjugated to Alexa 647 (Invitrogen). DAPI (4’,6-diamidino-
2-phenylindole) staining was used to demarcate the nucleus (0.1 mg/ml for 5 min) 
Cells were visualized using a Nikon A1 point-scanning laser confocal microscope 
(Nikon Instruments). Blinded quantification of MX2 cellular localization was 
determined visually for 100 randomly selected cells.  705 
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FIGURE LEGENDS 
 
 880 
Fig. 1. Multiple nucleoporins interact with the N-terminal domain of MX2 (N-
MX2). (A) A yeast two-hybrid (Y-2-H) screen was performed using a human 
leukocyte cDNA library to identify interacting proteins with WT or mutant RRR11-
13A N-MX2. Interacting partners were assigned a predicted biological score from 
A-F to assess the confidence of an interaction being specific (with A indicating very 885 
high confidence, and F indicating experimentally determined artifacts). (B) Co-
immunoprecipitation of candidate interacting proteins with MX2. 293T cells were 
co-transfected with HA-tagged WT or mutant RRR11-13A MX2 and FLAG-tagged 
candidate interactors from the Y-2-H screen. Cells were lysed and HA-tagged 
protein immunoprecipitated with anti-HA antibody. Co-transfection of FLAG-890 
tagged candidates with HA-tagged MX1 or GFP served as negative controls. 
Immunoblots of immunoprecipitated proteins (IP) were probed with anti-FLAG 
and anti-HA antibodies. As a control for protein expression, samples of lysate prior 
to immunoprecipitation (IN) were probed with anti-FLAG antibody. All 
experiments were performed at least three times. 895 
 
Fig. 2. NUP214 and TNPO1 are required for full anti-viral activity of MX2 in U87-
MG cells. U87-MG CD4+ CXCR4+ cells were transduced with EasiLV vectors 
expressing FLAG-tagged MX2 or Luciferase (control). After 48 h, transduced cells 
were transfected twice, 24 h apart, with 20 nM of specific siRNAs (a non-targeting 900 
siRNA was included as a control, CTRL). Expression of MX2 or Luciferase was then 
induced by treatment of cells with doxycycline (0.5 μg/ml) for ~72 h prior to 
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challenge with a HIV-1 based lentiviral vector expressing GFP (HIV-1/GFP). 
Transduction efficiency was assessed 48 h post challenge by flow-cytometry. (A) 
NUP358, NUP214, NUP98, hRIP, PNRC1, KLHL6, NUP62, NUP153, TNPO1 or 905 
TNPO3 were depleted independently or in pairs and MX2 anti-viral activity was 
analyzed. A dotted line indicates the fold inhibition of HIV-1 obtained in cells 
treated with CTRL siRNA. Conditions where NUP214 or TNPO1 where depleted 
are highlighted in red and blue, respectively, while depletion of both is indicated 
in purple. (B-C) Effect of siRNA-mediated depletion of NUP214 and/or TNPO1 on 910 
the anti-HIV-1 activity of MX2. In C, the same data as in B are represented as MX2-
mediated fold inhibition by dividing %GFP+ luciferase expressing cells by %GFP+ 
MX2 expressing cells (n=3; mean ± standard deviation (SD); *p-value < 0.05; 
paired t-test to CTRL siRNA). (D) The effect of NUP214 and/or TNPO1 depletion 
on MLV infectivity in the presence of MX2 was studied by challenging siRNA-915 
transfected cells with an MLV based vector expressing GFP. (E) Immunoblot 
analysis of MX2 expressing cells from the experiment described in B-D, indicating 
levels of FLAG-tagged MX2 and endogenous NUP214 (detected using mab414) 
and TNPO1 after siRNA treatment. HSP90 is included as a loading control. 
 920 
Fig. 3. Multiple nucleoporins and transport receptors are required for anti-viral 
activity of MX2 in HeLa cells. (A) HeLa cells were stably transduced with lentiviral 
vectors constitutively expressing FLAG-tagged MX2 or CD8 (negative control), and 
transduced cells selected by treatment with 1 μg/ml puromycin for 48 h. After 
selection, transduced cells were transfected twice, 24 h apart, with 20 nM siRNA 925 
targeting individual nucleoporins or transport receptors. A non-targeting siRNA 
was included as a control, CTRL. After 48 h, cells were challenged with HIV-1/GFP 
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and transduction efficiency assessed by flow cytometry after a further 48 h post 
challenge. (B) the same data as in A are represented as fold MX2-mediated 
inhibition, calculated as in Fig. 2 (n= 3; mean ± SD; *p-value < 0.05; paired t-test). 930 
 
Fig. 4. MX2 interacts with TNPO1 via RRR11-13, and endogenous FG-
nucleoporins. (A) Interaction of MX2 with endogenous FG-nucleoporins. U87-MG 
CD4+ CXCR4+ cells were treated with siRNA targeting NUP214 or a non-targeting 
siRNA (CTRL) as described in Fig. 2 and incubated for ~48 h prior to culture with 935 
or without IFN (500 U/ml) for a further 24 h. Treated cells were lysed, and mouse 
monoclonal mab414 used to extract FG-nucleoporins NUP358, NUP214, NUP153 
and NUP62. An anti-GFP mouse monoclonal was included as a control (CTRL). 
Immunoblots were performed on immunoprecipitated material (IP) to detect the 
presence of associated MX2, and on samples of lysate prior to precipitation 940 
(INPUT). (B) TNPO1 interacts with MX2 via RRR11-13. 293T cells were co-
transfected with HA-tagged WT MX2 or mutant RRR11-13A MX2 and FLAG-tagged 
TNPO1. Cells were lysed and HA-tagged protein immunoprecipitated with anti-HA 
antibody. HA-tagged MX1 or GFP were included as negative controls. 
Immunoblots of immunoprecipitated protein (IP) were probed with anti-FLAG 945 
and anti-HA antibodies. As a control for protein expression, samples of lysate prior 
to immunoprecipitation (IN) were probed with anti-FLAG antibody. (C) TNPO1 
interacts with MX2 but not the CTD of NUP214. A similar experiment was 
performed in 293T cells as described in B, except that a FLAG-tagged construct 
encoding the 35 kDa CTD of NUP214 was co-expressed with HA-tagged constructs 950 
expressing TNPO1, MX1 or MX2. Immunoprecipitation was performed with an 
anti-HA antibody (D) MX2 interacts with NUP214 CTD and TNPO1 after FLAG 
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immunoprecipitation. In 293T cells, a similar experiment was performed as 
described in B and C except that HA-tagged MX2 was co-expressed with FLAG-
tagged NUP214 CTD, TNPO1 or GFP and immunoprecipitation of cell lysate 955 
performed with an anti-FLAG antibody. All experiments were done at least three 
times. 
 
Fig. 5. Endogenous MX2 requires NUP214 and TNPO1 for a full anti-viral function. 
(A) U87-MG cells transduced with a CRISPR-Cas9 control guide RNA were 960 
transfected twice with a control siRNA (CTRL) or siRNAs targeting MX2, NUP214 
and/or TNPO1, and treated or not with 1000 U/ml of IFN, prior to infection with 
an HIV-1/GFP lentiviral vector. On the left, the percentage of infected cells 
calculated by flow cytometry and the fold inhibition of infection due to IFN 
treatment are shown (n= 4; mean ± SD; *p-value < 0.05; (ns) non-significant; 965 
paired t-test). On the right is an immunoblot from a representative experiment, 
showing depletion of the indicated proteins. (B) Same experiment as in A, but 
using U87-MG cells where the MX2 alleles were disrupted using CRISPR-Cas9 
genome editing (n= 4; mean ± SD; *p-value < 0.05; (ns) non-significant; paired t-
test). (C) Primary CD4+ T cells were isolated from 4 donors, transduced with 970 
shRNAs targeting MX2, NUP214, TNPO1 or a control shRNA (CTRL) and treated or 
not with 3000 U/ml of IFN. 24 h later, cells were challenged with NL4.3/Nef-
IRES-Renilla and luciferase activity determined 48 h later. The mean of three 
technical replicates are shown for each donor on the left, and the fold inhibition of 
infection (no IFN/IFN) on the right. 975 
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Fig. 6. Depletion of NUP214 and TNPO1 disrupts nuclear envelope accumulation 
of MX2. (A) HeLa cells stably expressing MX2 bearing a C-terminal FLAG tag were 
transfected with siRNA targeting NUP214 and/or TNPO1 or a non-targeting siRNA 
(CTRL) as described in Fig. 3, and then seeded onto glass coverslips. Localization 980 
of MX2, and endogenous NUP214 and TNPO1 was visualized by fluorescence 
confocal microscopy, using anti-FLAG, anti-NUP214, and anti-TNPO1 antibodies 
respectively. DAPI was used to stain the nuclei. Scale bar represents 20 μm. (B) 
Predominant cellular localization of MX2 was determined visually (blinded) using 
a 60x objective and an average of 100 cells, randomly selected (mean ± SD; *p-985 
value < 0.05; paired t-test).  
 
Fig. 7. Nucleoporins interacting with MX2 are located at the cytoplasmic face of 
the nuclear pore. Schematic diagram indicating the structure and organization of 
the nuclear pore complex as described in Hoelz et al (22). Nucleoporins 990 
interacting with MX2 (identified by Y-2-H screening) are shown in red. 
Nucleoporins required for MX2 activity (defined as those for which specific 
depletion elicited >50% reduction in MX2 dependent inhibition of HIV-1, in either 
HeLa or U87-MG cells) are shown in bold. Nucleoporins that interact with MX2 
and are required for MX2 inhibition are shown in red and bold. 995 
 
 
 
S Fig. 1. Screen for co-factors required for full anti-viral activity of MX2 in U87-MG 
cells. U87-MG CD4+ CXCR4+ cells were transduced with EasiLV vectors expressing 1000 
FLAG-tagged MX2 or Luciferase (control). After 48 h, transduced cells were 
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transfected twice, 24 h apart, with a panel of siRNAs at a concentration of 20 nM. 
For the first siRNA transfection, cells were treated with specific siRNAs, most of 
these targeting candidate interactors from the Y-2-H screen (Fig. 1) including 
NUP358, NUP214, NUP98, hRIP, PNRC1, KLHL6 and a non-targeting siRNA was 1005 
included as a control (CTRL). For the second siRNA transfection, cells were treated 
with a panel of specific siRNAs targeting a number of nucleoporins and transport 
receptors in addition to the Y-2-H candidates. Expression of MX2 or Luciferase 
was then induced by treatment of cells with doxycycline (0.5 μg/ml) for ~72 h 
prior to challenge with a HIV-1 based lentiviral vector expressing GFP (HIV-1010 
1/GFP). Transduction efficiency was assessed 48 h post challenge by flow-
cytometry. Data are representative of two independent experiments.  
 
S Fig. 2. (accompanies Fig. 2). Efficiency of siRNA-mediated depletion of 
endogenous proteins in U87-MG cells. U87-MG CD4+ CXCR4+ cells were 1015 
transfected twice, 24 h apart, with 20 nM siRNA targeting NUP358, NUP214, 
NUP153, NUP62, NUP98, hRIP, KLHL6, NUPL2 and PNRC1. After 72 h, protein 
levels were analyzed by immunoblotting, with α-tubulin or HSP90 included as 
loading controls. No reduction in target protein abundance was observed after 
treatment with siRNA targeting NUPL2, and PNRC1 expression was not detectable 1020 
by immunoblot.  
 
S Fig. 3 (accompanies Fig. 3). Efficiency of siRNA-mediated depletion of 
endogenous proteins in HeLa cells. HeLa cells were transfected twice, 24 h apart, 
with 20 nM siRNA targeting NUP358, NUP214, NUP153, NUP62, NUP98, hRIP, 1025 
KLHL6, PNRC1, NUP88, NUP188, TNPO1, TNPO3 and NUP214 together with 
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TNPO1 (and CTRL siRNA). After 72 h, protein levels were analyzed by 
immunoblotting, with α-tubulin included as loading control. 
 
 1030 
 
S Table 1. (accompanies Fig. 1A). Complete list and PBS of known genes identified 
in the yeast-two-hybrid screens. 
 
S Table 2 (accompanies Figs. 1B and 4B). Quantification of co-1035 
immunoprecipitation of FLAG-tagged NUP214-CTD, NUP98, NUPL2, RUNX3, 
PNRC1, KLHL6, hRIP or TNPO1 with HA-tagged GFP, MX1, MX2 or RRR11-13A 
MX2. Values represent the ratio between protein input (IN) and the protein 
detected in the IP, normalized against wild-type MX2 interactions.  
 1040 
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